BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 29797665)

  • 1. Fusion status in patients with lymph node-positive (N1) alveolar rhabdomyosarcoma is a powerful predictor of prognosis: Experience of the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG).
    Gallego S; Zanetti I; Orbach D; Ranchère D; Shipley J; Zin A; Bergeron C; de Salvo GL; Chisholm J; Ferrari A; Jenney M; Mandeville HC; Rogers T; Merks JHM; Mudry P; Glosli H; Milano GM; Ferman S; Bisogno G;
    Cancer; 2018 Aug; 124(15):3201-3209. PubMed ID: 29797665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alveolar rhabdomyosarcoma with regional nodal involvement: Results of a combined analysis from two cooperative groups.
    Gallego S; Chi YY; De Salvo GL; Li M; Merks JHM; Rodeberg DA; van Scheltinga ST; Mascarenhas L; Orbach D; Jenney M; Million L; Minard-Colin V; Wolden S; Zanetti I; Parham DM; Mandeville H; Venkatramani R; Bisogno G; Hawkins DS;
    Pediatr Blood Cancer; 2021 Mar; 68(3):e28832. PubMed ID: 33245207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy and prognostic significance of regional lymph node involvement in embryonal rhabdomyosarcoma: a report from the European paediatric Soft tissue sarcoma Study Group.
    Ben-Arush M; Minard-Colin V; Scarzello G; Fajardo RD; Terwisscha Van Scheltinga S; Bernier V; Jenney M; Gallego S; Zanetti I; Cesen M; Merks JHM; Bisogno G
    Eur J Cancer; 2022 Sep; 172():119-129. PubMed ID: 35763871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metastatic rhabdomyosarcoma with exclusive distant lymph node involvement: A European Pediatric Soft tissue sarcoma Study Group (EpSSG) report.
    Mercolini F; Merks JHM; Minard-Colin V; Cameron A; van Scheltinga SEJT; Sher O; Fichera G; Orbach D; Glosli H; Coppadoro B; Gallego S; Chisholm JC; Bisogno G
    Pediatr Blood Cancer; 2023 Mar; 70(3):e30143. PubMed ID: 36519598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance and tumor biology of regional lymph node disease in patients with rhabdomyosarcoma: a report from the Children's Oncology Group.
    Rodeberg DA; Garcia-Henriquez N; Lyden ER; Davicioni E; Parham DM; Skapek SX; Hayes-Jordan AA; Donaldson SS; Brown KL; Triche TJ; Meyer WH; Hawkins DS
    J Clin Oncol; 2011 Apr; 29(10):1304-11. PubMed ID: 21357792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-parameningeal head and neck rhabdomyosarcoma in children, adolescents, and young adults: Experience of the European paediatric Soft tissue sarcoma Study Group (EpSSG) - RMS2005 study.
    Glosli H; Bisogno G; Kelsey A; Chisholm JC; Gaze M; Kolb F; McHugh K; Shipley J; Gallego S; Merks JHM; Smeele LE; Mandeville H; Ferrari A; Minard-Colin V; Corradini N; Jenney M; Zanetti I; De Salvo GL; Orbach D;
    Eur J Cancer; 2021 Jul; 151():84-93. PubMed ID: 33971448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children's Oncology Group.
    Rudzinski ER; Anderson JR; Chi YY; Gastier-Foster JM; Astbury C; Barr FG; Skapek SX; Hawkins DS; Weigel BJ; Pappo A; Meyer WH; Arnold MA; Teot LA; Parham DM
    Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28521080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival outcomes of patients with localized FOXO1 fusion-positive rhabdomyosarcoma treated on recent clinical trials: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Heske CM; Chi YY; Venkatramani R; Li M; Arnold MA; Dasgupta R; Hiniker SM; Hawkins DS; Mascarenhas L
    Cancer; 2021 Mar; 127(6):946-956. PubMed ID: 33216382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group.
    Sorensen PH; Lynch JC; Qualman SJ; Tirabosco R; Lim JF; Maurer HM; Bridge JA; Crist WM; Triche TJ; Barr FG
    J Clin Oncol; 2002 Jun; 20(11):2672-9. PubMed ID: 12039929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial.
    Bisogno G; De Salvo GL; Bergeron C; Gallego Melcón S; Merks JH; Kelsey A; Martelli H; Minard-Colin V; Orbach D; Glosli H; Chisholm J; Casanova M; Zanetti I; Devalck C; Ben-Arush M; Mudry P; Ferman S; Jenney M; Ferrari A;
    Lancet Oncol; 2019 Nov; 20(11):1566-1575. PubMed ID: 31562043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adolescents and young adults with rhabdomyosarcoma treated in the European paediatric Soft tissue sarcoma Study Group (EpSSG) protocols: a cohort study.
    Ferrari A; Chisholm JC; Jenney M; Minard-Colin V; Orbach D; Casanova M; Guillen G; Glosli H; van Rijn RR; Schoot RA; Cameron AL; Rogers T; Alaggio R; Ben-Arush M; Mandeville HC; Devalck C; Defachelles AS; Coppadoro B; Bisogno G; Merks JHM
    Lancet Child Adolesc Health; 2022 Aug; 6(8):545-554. PubMed ID: 35690071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of fusion status, Oberlin risk factors, local and maintenance treatment in pediatric and adolescent patients with metastatic rhabdomyosarcoma: Data of the European Soft Tissue Sarcoma Registry SoTiSaR.
    Heinz AT; Schönstein A; Ebinger M; Fuchs J; Timmermann B; Seitz G; Vokuhl C; Münter M; Pajtler KW; Stegmaier S; von Kalle T; Kratz CP; Ljungman G; Juntti H; Klingebiel T; Koscielniak E; Sparber-Sauer M;
    Pediatr Blood Cancer; 2024 Jan; 71(1):e30707. PubMed ID: 37814424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perianal/perineal rhabdomyosarcoma: Results of the SIOP MMT 95, Italian RMS 96, and EpSSG RMS 2005 studies.
    Rogers T; Zanetti I; Coppadoro B; Martelli H; Jenney M; Minard-Colin V; Terwisscha van Scheltinga SEJ; Skerritt C; Fajardo RD; Guérin F; Kelsey A; Merks JHM; Mandeville H; Guillén G; Glosli H; De Corti F; Bisogno G
    Pediatr Blood Cancer; 2022 Sep; 69(9):e29739. PubMed ID: 35460336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Local staging and treatment in extremity rhabdomyosarcoma. A report from the EpSSG-RMS2005 study.
    Terwisscha van Scheltinga SEJ; Wijnen MHWA; Martelli H; Rogers T; Mandeville H; Gaze MN; McHugh K; Corradini N; Orbach D; Jenney M; Kelsey A; Chisholm J; Gallego S; Glosli H; Ferrari A; Zanetti I; De Salvo GL; Minard-Colin V; Bisogno G; van Noesel MM; Merks HHM
    Cancer Med; 2020 Oct; 9(20):7580-7589. PubMed ID: 32869534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of regional lymph node involvement in childhood extremity rhabdomyosarcoma.
    Mandell L; Ghavimi F; LaQuaglia M; Exelby P
    Med Pediatr Oncol; 1990; 18(6):466-71. PubMed ID: 2233517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A clinicopathologic study of head and neck rhabdomyosarcomas showing FOXO1 fusion-positive alveolar and MYOD1-mutant sclerosing are associated with unfavorable outcome.
    Owosho AA; Huang SC; Chen S; Kashikar S; Estilo CL; Wolden SL; Wexler LH; Huryn JM; Antonescu CR
    Oral Oncol; 2016 Oct; 61():89-97. PubMed ID: 27688110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children's oncology group report.
    Skapek SX; Anderson J; Barr FG; Bridge JA; Gastier-Foster JM; Parham DM; Rudzinski ER; Triche T; Hawkins DS
    Pediatr Blood Cancer; 2013 Sep; 60(9):1411-7. PubMed ID: 23526739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diffuse myogenin expression by immunohistochemistry is an independent marker of poor survival in pediatric rhabdomyosarcoma: a tissue microarray study of 71 primary tumors including correlation with molecular phenotype.
    Heerema-McKenney A; Wijnaendts LC; Pulliam JF; Lopez-Terrada D; McKenney JK; Zhu S; Montgomery K; Mitchell J; Marinelli RJ; Hart AA; van de Rijn M; Linn SC
    Am J Surg Pathol; 2008 Oct; 32(10):1513-22. PubMed ID: 18708938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment and characterization of a novel alveolar rhabdomyosarcoma cell line, NCC-aRMS1-C1.
    Sin Y; Yoshimatsu Y; Noguchi R; Tsuchiya R; Sei A; Ono T; Toki S; Kobayashi E; Arakawa A; Sugiyama M; Yoshida A; Kawai A; Kondo T
    Hum Cell; 2020 Oct; 33(4):1311-1320. PubMed ID: 32715445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PAX-FOXO1 fusion status in children and adolescents with alveolar rhabdomyosarcoma: Impact on clinical, pathological, and survival features.
    Raze T; Lapouble E; Lacour B; Guissou S; Defachelles AS; Gaspar N; Delattre O; Pierron G; Desandes E
    Pediatr Blood Cancer; 2023 Apr; 70(4):e30228. PubMed ID: 36722003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.